Artiva Biotherapeutics to stop developing its lead experimental cell therapy after two patient deaths and reduce its workforce by 94%

Observed price moves

• ARTV-4.36%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.